Simultaneous genotyping for human platelet antigen systems and HLA-A and HLA-B loci by targeted next-generation sequencing

Wang, Jielin; You, Xuan; He, Yanming; Hong, Xiaozhen; He, Ji; Tao, Sudan; Zhu, Faming

doi:10.3389/fimmu.2022.945994

Cited by 5 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with refractoriness to random donor platelet transfusion often require platelet products that are partially HLA‐matched. Matching of class I antigens HLA‐A and B and matching human platelet antigens is a common approach to platelet transfusion refractoriness 11 . Maintaining a roster of willing platelet donors for this purpose remains a challenge for many blood operators.…”

Section: Discussionmentioning

confidence: 99%

“…Matching of class I antigens HLA-A and B and matching human platelet antigens is a common approach to platelet transfusion refractoriness. 11 Maintaining a roster of willing platelet donors for this purpose remains a challenge for many blood operators. A source of willing platelet donors could be found within the pool of redundant registrants.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HLA‐haplotype redundancy and rareness in Canadian Blood Services' Stem Cell Registry and Cord Blood Bank: Novel metrics for optimizing utility

Bailey,

Blake,

Ganz

et al. 2023

Transfusion

View full text Add to dashboard Cite

BackgroundThe utility of unrelated donor registries that support allogeneic hematopoietic cell transplantation could be optimized through greater understanding of redundancy and rareness of HLA phenotypes.MethodsHLA phenotype rareness was determined using known HLA haplotype frequencies. Donor redundancy was determined through pairwise comparison of donor HLA profiles within an inventory.ResultsAmong 61,730 registrants in the Canadian Blood Services (CBS) Stem Cell Registry (SCR) with high resolution HLA typing at 5 loci, 6.6% of HLA phenotypes were redundant with variation across ethnic groups (8.3% of Caucasian phenotypes; 8% of Native American/First Nations, 4.4% of Asia‐Pacific Islanders (API), 2.1% of Hispanic, 0.7% of African‐American (AFA), and 4.5% of other ethnicities). A total of 18.5% of registrants had redundant HLA phenotypes with variation across ethnic groups. All 3716 cord blood units in the CBS's cord blood bank (CBB) had high resolution HLA typing at 5 loci and 202 units were redundant (5.4%) comprising 78 HLA phenotypes, with varying rareness. Repeated HLA phenotypes were from Caucasian donors (77%), multiple ethnicity (13%), API (9%), and AFA (1%). Registrants and CBUs with AFA ethnicity had the rarest phenotypes while Caucasian ethnicity was associated with the most common HLA phenotypes.ConclusionsRedundancy was greater in the SCR compared to the CBB and was most common with CAU ethnicity. Recruiting non‐Caucasian registrants and continued cord blood banking should reduce redundancy. A sub‐inventory of redundant donors and cord blood units could support new uses for donor‐supported cellular therapies that do not require HLA matching.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

HLA‐haplotype redundancy and rareness in Canadian Blood Services' Stem Cell Registry and Cord Blood Bank: Novel metrics for optimizing utility

Bailey,

Blake,

Ganz

et al. 2023

Transfusion

View full text Add to dashboard Cite

show abstract

A case study of a patient with platelet transfusion refractoriness (PTR) combined with human leucocyte antigen (HLA) antibody positivity during hepatic arterial infusion chemotherapy in conjunction with the ‘atezolizumab plus bevacizumab’ regimen

Xie,

Huang,

Liu

2024

Nursing in Critical Care

View full text Add to dashboard Cite

Hepatic arterial infusion chemotherapy in conjunction with the combination therapy of atezolizumab (T) and bevacizumab (A) is widely used in hepatocellular carcinoma. Some adverse events such as hypertension, weakness and elevated transaminase levels occurred during treatment, while there is currently no reported case about thrombocytopenia with concomitant HLA antibody‐positive PTR. We summarize the critical care nursing experience of a patient with PTR because of HLA antibody positivity during hepatic arterial infusion chemotherapy in conjunction with atezolizumab plus bevacizumab (T + A) regimen. This paper explains the nursing measures for patients with severe thrombocytopenia and proposes nursing measures for situations where conventional treatments are ineffective. Key nursing points include the administration of intravenous immunoglobulin (IVIG) and HLA‐compatible platelets, prevention of complications, psychological care, oral care, and skin management. Through systematic treatment and targeted nursing care, the patient's platelet count rebounded after 9 days, leading to a successful recovery and discharge. Subsequent follow‐up assessments revealed the patient's sustained well‐being. Thrombocytopenia is a potential adverse reaction during the treatment of liver cancer. When platelet transfusion is ineffective, vigilance is necessary for the possibility of HLA positivity, and prompt symptomatic management is warranted.

show abstract

Establishment and Application of a Multiplex PCR NGS Method for the Genotyping of HLA‐Class I and HPA

He,

Wang,

et al. 2024

HLA

View full text Add to dashboard Cite

Selecting compatible HLA‐Class I and/or HPA platelets based on genotyping could alleviate immune platelet transfusion refractoriness (PTR). A fast and reliable method of HLA‐Class I and HPA genotyping is necessary to construct a platelet donor bank with known HLA‐Class I and HPA genotypes. Ten pairs of specific primers for HLA‐A, HLA‐B, HLA‐C, HPA‐1 through HPA‐6w, HPA‐15 and HPA‐21w were designed. The appropriate fragments were optimised for amplification in a single multiplex reaction. After a cleanup step using paramagnetic beads, the amplicon library was prepared and sequenced. To validate the accuracy of the developed method, commercial NGS kits for the genotyping of HLA‐A, HLA‐B and HLA‐C and the TaqMan real‐time PCR method in‐house for the genotyping of HPA‐1 through HPA‐6w, HPA‐15 and HPA‐21w were used to detect all the specimens in parallel. A total of 386 specimens were detected and the results of genotyping HLA‐A, HLA‐B, HLA‐C and HPA‐1 through HPA‐6w, HPA‐15 and HPA‐21w were obtained simultaneously, which is 100% consistent between the two methods. Four new HLA alleles, HLA‐A*11:451, HLA‐A*30:01:26, HLA‐B*39:201 and HLA‐B*40:538, were also reconfirmed. Two novel SNVs, c.2671C > T and c.2681T > G, in the coding region of ITGA2B were detected, all of which are heterozygous in individuals. A novel NGS method based on multiplex PCR was established to detect HLA‐Class I and HPA simultaneously, which is high‐throughput, rapid and accurate and could be applied to build a platelet donor bank.

show abstract

Simultaneous genotyping for human platelet antigen systems and HLA-A and HLA-B loci by targeted next-generation sequencing

Cited by 5 publications

References 48 publications

HLA‐haplotype redundancy and rareness in Canadian Blood Services' Stem Cell Registry and Cord Blood Bank: Novel metrics for optimizing utility

HLA‐haplotype redundancy and rareness in Canadian Blood Services' Stem Cell Registry and Cord Blood Bank: Novel metrics for optimizing utility

A case study of a patient with platelet transfusion refractoriness (PTR) combined with human leucocyte antigen (HLA) antibody positivity during hepatic arterial infusion chemotherapy in conjunction with the ‘atezolizumab plus bevacizumab’ regimen

Establishment and Application of a Multiplex PCR NGS Method for the Genotyping of HLA‐Class I and HPA

Contact Info

Product

Resources

About